Literature DB >> 22555162

Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals.

Louise Nygaard Clausen1, Karen Astvad, Steen Ladelund, Mette Vang Larsen, Kristian Schønning, Thomas Benfield.   

Abstract

OBJECTIVE: We hypothesized that hepatitis C virus (HCV) load and genotype may influence all-cause mortality in HIV-HCV-coinfected individuals. DESIGN AND METHODS: Observational prospective cohort study. Mortality rates were compared in a time-updated multivariate Poisson regression analysis.
RESULTS: We included 264 consecutive HIV-HCV-coinfected individuals. During 1143 person years at risk (PYR) 118 individuals died [overall mortality rate 10 (95% confidence interval; 8, 12)/100 PYR]. In multivariate analysis, a 1 log increase in HCV viral load was associated with a 30% higher mortality risk [adjusted mortality rate ratio (aMRR): 1.30 (1.10,1.54)] when adjusted for sex, age, HIV exposure group, CD4 cell count, HIV RNA, HCV genotype and interleukin (IL)-28B genotype. Further, HCV genotype 3 vs. 1 [aMRR: 1.83 (1.12, 2.98)] and HIV RNA [aMRR: 3.14 (1.37,7.17) for undetectable vs. just detectable HIV RNA] were independent predictors of mortality, whereas a higher CD4 cell count was associated with a 41% reduction in mortality rate per 50 cell increase between 0 and 200 cells/μl [aMRR: 0.59 (0.48, 0.72)] and a 10% reduction for increases above 200 cells/μl [aMRR: 0.90 (0.82-0.98)]. IL28B) CC genotype was associated with 54% higher mortality risk [aMRR: 1.54 (0.89, 3.82] compared to TT genotype.
CONCLUSION: High-HCV viral load, HCV genotype 3 and IL28B genotype CC had a significant influence on the risk of all-cause mortality among individuals coinfected with HIV-1. This may have consequences for the management of HIV-HCV-coinfected individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555162     DOI: 10.1097/QAD.0b013e3283553581

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

2.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

3.  Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients.

Authors:  Daniel Fuster; David Nunes; Debbie M Cheng; Richard Saitz; Jeffrey H Samet
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

4.  Influence of hepatitis C virus and IL28B genotypes on liver stiffness.

Authors:  Lene Fogt Lundbo; Louise Nygaard Clausen; Nina Weis; Kristian Schønning; Lene Rosenørn; Thomas Benfield; Peer Brehm Christensen
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

Review 5.  HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.

Authors:  Lars Peters; Amanda Mocroft; Jens Lundgren; Daniel Grint; Ole Kirk; Jürgen Rockstroh
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

6.  Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients.

Authors:  Jacqueline M McBride; Daniel Sheinson; Jenny Jiang; Nicholas Lewin-Koh; Barbara G Werner; Jennifer K L Chow; Xiaoning Wu; Jorge A Tavel; David R Snydman
Journal:  Open Forum Infect Dis       Date:  2019-01-14       Impact factor: 3.835

Review 7.  Pharmacogenomics of hepatitis C infections: personalizing therapy.

Authors:  David R Booth; Golo Ahlenstiel; Jacob George
Journal:  Genome Med       Date:  2012-12-26       Impact factor: 11.117

Review 8.  The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.

Authors:  F Bellanti; G Vendemiale; E Altomare; G Serviddio
Journal:  Clin Dev Immunol       Date:  2012-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.